评估生物标志物驱动疗法的基因组测试在瘤学中的成本
Jamie P Grossman1,2, Elizabeth A Sheppard2,3, Zhuofan Yan4
1Bayer Healthcare Pharmaceuticals Inc, Whippany, NJ, USA.
Oncology and therapy
|February 17, 2026
概括
使用下一代测序 (NGS) 的综合基因组分析 (CGP) 对许多癌症比单基因测试 (SGT) 更具成本效益. 这一发现支持在癌症分子分析的常规临床实践中扩大NGS的使用范围.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 卫生经济学 卫生经济学
背景情况:
- 基因组分析对癌症的诊断,监测和治疗至关重要.
- 通过下一代测序 (NGS) 进行综合基因组分析 (CGP),可以同时进行多基因测试,从而减少时间,成本和样本使用.
- 基因组分析的高成本可能会阻碍其广泛的临床采用.
研究的目的:
- 为了比较目标小组NGS与单个单基因测试 (SGT) 的成本效益.
- 评估NGS和SGT在各种癌症类型中的每位正确确诊断患者 (CCIP) 的成本.
主要方法:
- 开发一个成本计算器,比较NGS和SGT.
- 包括来自ESMO分子标临床可操作性量表 (2024年更新) 的30多个生物标志物.
- 利用敏感性,特异性,生物标志物流行率和预测所需数量 (NNP) 度量来估计14种晚期恶性瘤的CCIP,结果以欧元和美元 (膨胀到2025年).
主要成果:
- 在欧元中,NGS在转移性结直肠癌 (mCRC),晚期前列腺癌,晚期胰腺管腺癌 (PDAC),晚期胆管癌 (CC),晚期软组织肉瘤 (STS),晚期甲状腺癌和未知原发性癌症 (CUP) 中的CCIP低于SGT.
- 在美元中,NGS还显示了比SGT对所有上述瘤类型的更有利的CCIP,除了先进的CC.
- 结果被膨胀到2025年的价值.
结论:
- 成本计算器表明,NGS在几种恶性瘤中的分子分析中比SGT更具成本效益.
- 这些发现表明,在癌症患者的常规临床实践中,增加NGS的利用机会.
- 通过NGS的CGP可以成为个性化瘤学的宝贵工具.
更多相关视频
13:24Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
12.3K
06:40Author Spotlight: Cost-Effective Transcriptomic Drug Screening - Unlocking New Targets
Published on: February 23, 2024
1.8K
相关概念视频
01:29Pharmacogenomics: Identification of New Drug Targets
20
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
20
02:50Combination Therapies and Personalized Medicine
6.2K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.2K